Literature DB >> 25478369

Adverse reactions of ferric carboxymaltose.

Harish Thanusubramanian1, Navin Patil2, Smita Shenoy3, K L Bairy4, Yashdeep Sarma5.   

Abstract

The author reports a 55-year-old female diagnosed of chronic kidney disease grade-5 with associated co-morbidities like type 2 diabetes mellitus, diabetic retinopathy and hypothyroidism was admitted for arteriovenous fistula construction. She was started on ferric carboxymaltose for the treatment of anaemia. She was given a test dose before administering the drug intravenously and she did not develop any reaction. The drug ferric carboxymaltose was then administered over a period of one hour. About half an hour after drug administration, the patient developed breathlessness and myalgia. After half hour of the above episode of breathlessness and myalgia she also developed vomiting (one episode). Patient was managed with oxygen therapy, IV fluids and other drugs like corticosteroids, phenaramine maleate and nalbuphine which controlled the above symptoms.

Entities:  

Keywords:  Anemia; Breathlessness; Chronic kidney disease; RFT (renal function test)

Year:  2014        PMID: 25478369      PMCID: PMC4253187          DOI: 10.7860/JCDR/2014/9499.5015

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  8 in total

1.  Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.

Authors:  George R Bailie
Journal:  Arzneimittelforschung       Date:  2010

Review 2.  New erythropoiesis-stimulating agents and new iron formulations.

Authors:  Francesco Locatelli; Lucia Del Vecchio
Journal:  Contrib Nephrol       Date:  2011-05-23       Impact factor: 1.580

Review 3.  Maximizing the erythropoietin response: iron strategies.

Authors:  Mayoor V Prabhu; Aditi Nayak; G Sridhar; S V Subhramanyam; K S Nayak
Journal:  Contrib Nephrol       Date:  2012-05-25       Impact factor: 1.580

4.  Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.

Authors:  Chaim Charytan; Marializa V Bernardo; Todd A Koch; Angelia Butcher; David Morris; David B Bregman
Journal:  Nephrol Dial Transplant       Date:  2012-12-05       Impact factor: 5.992

Review 5.  Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?

Authors:  Iain C Macdougall
Journal:  Curr Med Res Opin       Date:  2010-02       Impact factor: 2.580

Review 6.  Use of intravenous iron supplementation in chronic kidney disease: an update.

Authors:  Iain C Macdougall; Peter Geisser
Journal:  Iran J Kidney Dis       Date:  2013-01       Impact factor: 0.892

7.  An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.

Authors:  Paul D Wilson; Adam Hutchings; Aruna Jeans; Iain C Macdougall
Journal:  J Med Econ       Date:  2012-10-10       Impact factor: 2.448

8.  A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

Authors:  Wajeh Y Qunibi; Carlos Martinez; Mark Smith; Joseph Benjamin; Antoinette Mangione; Simon D Roger
Journal:  Nephrol Dial Transplant       Date:  2010-10-07       Impact factor: 5.992

  8 in total
  2 in total

1.  The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model.

Authors:  Jorge E Toblli; Gabriel Cao; Margarita Angerosa
Journal:  J Clin Diagn Res       Date:  2015-12-01

2.  Iron Deficiency Anemia with Menorrhagia: Ferric Carboxymaltose a Safer Alternative to Blood Transfusion.

Authors:  Vineet Mishra; Ruchika Verneker; Khushali Gandhi; Sumesh Choudhary; Sunita Lamba
Journal:  J Midlife Health       Date:  2018 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.